Ardelyx Inc

41X

Company Profile

  • Business description

    Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

  • Contact

    400 Fifth Avenue
    Suite 210
    WalthamMA02451
    USA

    T: +1 510 745-1700

    E: [email protected]

    https://www.ardelyx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    395

Stocks News & Analysis

stocks

Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%

We see faster cloud growth and improved longer-term profitability for Alphabet.
stocks

Overvalued ASX mining giant

Solid start to 2026 but shares overvalued.
stocks

Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?

With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,317.2026.50-0.28%
CAC 408,225.630.15-0.00%
DAX 4024,239.8932.100.13%
Dow JONES (US)47,207.12472.511.01%
FTSE 1009,645.6267.050.70%
HKSE26,160.15192.170.74%
NASDAQ23,204.87263.071.15%
Nikkei 22549,299.65658.041.35%
NZX 50 Index13,391.5914.490.11%
S&P 5006,791.6953.250.79%
S&P/ASX 2009,019.0025.20-0.28%
SSE Composite Index3,950.3127.900.71%

Market Movers